title: Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease.
abstract: BACKGROUND
  The treatment of oligometastatic disease has become common as imaging techniques have advanced and the management of systemic disease has improved. Use of highly targeted, hypofractionated regimens of stereotactic body radiotherapy (SBRT) is now a primary management option for patients with oligometastatic disease.
  
  
  METHODS
  The properties of SBRT are summarized and the results of retrospective and prospective studies of SBRT use in the management of oligometastases are reviewed. Future directions of SBRT, including optimizing dose and fractionation schedules, are also discussed.
  
  
  RESULTS
  SBRT can deliver highly conformal, dosed radiation treatments for ablative tumors in a few treatment sessions. Phase 1/2 trials and retrospective institutional results support use of SBRT as a treatment option for oligometastatic disease metastasized to the lung, liver, and spine, and SBRT offers adequate toxicity profiles with good rates of local control. Future directions will involve optimizing dose and fractionation schedules for select histologies to improve rates of local control while limiting toxicity to normal structures.
  
  
  CONCLUSIONS
  SBRT offers an excellent management option for patients with oligometastases. However, additional research is still needed to optimize dose and fractionation schedules.
authors.forename: Kamran A
authors.initials: KA
authors.lastname: Ahmed
authors.affiliation: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Javier.TorresRoca@Moffitt.org.
authors.forename: Javier F
authors.initials: JF
authors.lastname: Torres-Roca
mesh_terms: D019468:Disease Management; D019583:Dose Fractionation, Radiation; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery*; D008175:Lung Neoplasms / Q000556:secondary / Q000601:surgery*; D011446:Prospective Studies; D011836:Radiation Tolerance; D016634:Radiosurgery; D012189:Retrospective Studies; D013125:Spinal Neoplasms / Q000556:secondary / Q000601:surgery*; D016896:Treatment Outcome